BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $11.05 billion. The enterprise value is $14.50 billion.
| Market Cap | 11.05B |
| Enterprise Value | 14.50B |
Important Dates
The last earnings date was Monday, November 2, 2026, after market close.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 193.69 million shares outstanding. The number of shares has decreased by -2.00% in one year.
| Current Share Class | 193.69M |
| Shares Outstanding | 193.69M |
| Shares Change (YoY) | -2.00% |
| Shares Change (QoQ) | -0.45% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 101.56% |
| Float | 192.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 10.30 |
| PS Ratio | 3.02 |
| Forward PS | 2.54 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 13.59 |
| P/FCF Ratio | 19.80 |
| P/OCF Ratio | 16.32 |
| PEG Ratio | 0.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.96, with an EV/FCF ratio of 25.99.
| EV / Earnings | n/a |
| EV / Sales | 3.97 |
| EV / EBITDA | 16.96 |
| EV / EBIT | 24.27 |
| EV / FCF | 25.99 |
Financial Position
The company has a current ratio of 2.44, with a Debt / Equity ratio of 0.67.
| Current Ratio | 2.44 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 4.85 |
| Debt / FCF | 7.51 |
| Interest Coverage | 4.37 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on invested capital (ROIC) is -2.70%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | 3.89% |
| Return on Invested Capital (ROIC) | -2.70% |
| Return on Capital Employed (ROCE) | 6.00% |
| Weighted Average Cost of Capital (WACC) | 3.59% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$5,934 |
| Employee Count | 3,221 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 1.08 |
Taxes
In the past 12 months, BMRN has paid $62.78 million in taxes.
| Income Tax | 62.78M |
| Effective Tax Rate | 143.78% |
Stock Price Statistics
The stock price has increased by +10.88% in the last 52 weeks. The beta is 0.23, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +10.88% |
| 50-Day Moving Average | 59.54 |
| 200-Day Moving Average | 58.45 |
| Relative Strength Index (RSI) | 49.59 |
| Average Volume (20 Days) | 2,586,041 |
Short Selling Information
The latest short interest is 12.05 million, so 6.22% of the outstanding shares have been sold short.
| Short Interest | 12.05M |
| Short Previous Month | 11.52M |
| Short % of Shares Out | 6.22% |
| Short % of Float | 6.25% |
| Short Ratio (days to cover) | 5.25 |
Income Statement
In the last 12 months, BMRN had revenue of $3.66 billion and -$19.12 million in losses. Loss per share was -$0.10.
| Revenue | 3.66B |
| Gross Profit | 1.94B |
| Operating Income | 597.44M |
| Pretax Income | 43.67M |
| Net Income | -19.12M |
| EBITDA | 854.99M |
| EBIT | 597.44M |
| Loss Per Share | -$0.10 |
Balance Sheet
The company has $736.01 million in cash and $4.19 billion in debt, with a net cash position of -$3.45 billion or -$17.83 per share.
| Cash & Cash Equivalents | 736.01M |
| Total Debt | 4.19B |
| Net Cash | -3.45B |
| Net Cash Per Share | -$17.83 |
| Equity (Book Value) | 6.26B |
| Book Value Per Share | 32.30 |
| Working Capital | 2.32B |
Cash Flow
In the last 12 months, operating cash flow was $676.62 million and capital expenditures -$118.75 million, giving a free cash flow of $557.86 million.
| Operating Cash Flow | 676.62M |
| Capital Expenditures | -118.75M |
| Depreciation & Amortization | 257.55M |
| Net Borrowing | 3.64B |
| Free Cash Flow | 557.86M |
| FCF Per Share | $2.88 |
Margins
Gross margin is 53.21%, with operating and profit margins of 16.35% and -0.52%.
| Gross Margin | 53.21% |
| Operating Margin | 16.35% |
| Pretax Margin | 1.19% |
| Profit Margin | -0.52% |
| EBITDA Margin | 23.39% |
| EBIT Margin | 16.35% |
| FCF Margin | 15.26% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.00% |
| Shareholder Yield | 2.00% |
| Earnings Yield | -0.17% |
| FCF Yield | 5.05% |
Analyst Forecast
The average price target for BMRN is $90.78, which is 59.19% higher than the current price. The consensus rating is "Buy".
| Price Target | $90.78 |
| Price Target Difference | 59.19% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 14.77% |
| EPS Growth Forecast (3Y) | 34.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2 |
| Piotroski F-Score | 3 |